A61K 2239/31
Characterized by the route of administration
Official title: characterized by the route of administration
A61K2239/31 (Characterized by the route of administration) appears on 2,060 US grants and 4,420 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,060
- Published applications
- 4,420
- Assignees
- 1,464
- Inventors
- 6,672
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 5 | 0 |
| 1995 | 5 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 19 | 0 |
| 1999 | 10 | 0 |
| 2000 | 13 | 0 |
| 2001 | 8 | 8 |
| 2002 | 12 | 51 |
| 2003 | 9 | 45 |
| 2004 | 14 | 59 |
| 2005 | 11 | 52 |
| 2006 | 19 | 55 |
| 2007 | 11 | 28 |
| 2008 | 12 | 50 |
| 2009 | 16 | 46 |
| 2010 | 40 | 84 |
| 2011 | 26 | 69 |
| 2012 | 27 | 68 |
| 2013 | 41 | 85 |
| 2014 | 53 | 104 |
| 2015 | 52 | 125 |
| 2016 | 75 | 126 |
| 2017 | 72 | 151 |
| 2018 | 102 | 233 |
| 2019 | 90 | 295 |
| 2020 | 150 | 369 |
| 2021 | 148 | 435 |
| 2022 | 165 | 501 |
| 2023 | 193 | 424 |
| 2024 | 195 | 462 |
| 2025 | 253 | 276 |
| 2026 | 195 | 219 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013